Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

Softer market ignores Budget
Markets Market Close

Softer market ignores Budget

Post-Budget, all eyes are on the Reserve Bank's OCR announcement next Wednesday.

Jamie Gray 23 May 2025
Restaurant Brands ‘does not seem to care’: Shareholder
Retail

Restaurant Brands ‘does not seem to care’: Shareholder

At the fiery annual meeting, a shareholder called the Californian market a ‘sinkhole’.

Gregor Thompson 23 May 2025
Channel increases dividend, mulls ASX listing
Infrastructure

Channel increases dividend, mulls ASX listing

Dividend up from 11c to between 12c and 12.5c. 

Ian Llewellyn 23 May 2025
Oceania CEO hopes sales cadence eases investor concerns
Property

Oceania CEO hopes sales cadence eases investor concerns

Suzanne Dvorak is "very positive" sales momentum will continue. 

Gregor Thompson 23 May 2025